IM95m Cells

The IM95m cell line is derived from a moderately differentiated gastric adenocarcinoma and has been notable for its capacity to produce significant amounts of cytokines, particularly hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and interleukin-8 (IL-8). This property positions IM95m as a valuable model for exploring tumor-angiogenesis interactions and mechanisms of cancer proliferation and metastasis. The cell line exhibits an epithelial morphology with tight intercellular connections and a calculated doubling time of approximately 25 hours. IM95m was originally established from a gastric cancer specimen and has shown the capability to form tumors in vivo, indicating its tumorigenic potential.

IM95m’s ability to secrete high levels of HGF and VEGF is particularly relevant to studies on cancer progression, as these growth factors are key drivers of angiogenesis and tumor growth. The production of HGF is continuous and significant, which enhances the potential of IM95m to contribute insights into the behavior of HGF-driven cancer pathways. The secretion of these factors suggests a role for IM95m in the study of resistance mechanisms to targeted therapies, such as VEGFR inhibitors, where HGF-mediated signaling may play a role in diminishing treatment efficacy.

In addition to its production of angiogenesis-associated cytokines, IM95m has been evaluated for its response in experimental models involving tumor growth inhibition. Its expression profile supports investigations into therapeutic strategies that target both VEGF and HGF pathways simultaneously, an approach that could provide more comprehensive cancer treatment outcomes.